GeoVax Highlights Strategic Implications of Gedeptin for Checkpoint-Resistant Cancers

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, today emphasized the strategic importance of its Gedeptin platform in overcoming checkpoint-resistant cancers. The company's comments follow a recent publication in JCI Insight, which reported that Gene-Directed Enzyme-Prodrug Therapy (GDEPT) can enhance checkpoint inhibitor responses and generate systemic anti-tumor immunity in preclinical models of triple-negative breast cancer.

Checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer treatment, but many tumors remain unresponsive due to limited immune infiltration and immunosuppressive microenvironments. These 'cold' tumors represent a significant barrier to effective immunotherapy. GeoVax Chairman and CEO David Dodd noted, 'One of the most significant challenges in oncology today is the cold tumor barrier. Checkpoint inhibitors can be highly effective when sufficient immune activity already exists within a tumor. However, many tumors remain largely invisible to the immune system.'

GeoVax recently explored this challenge in an Onco'Zine commentary. The company views Gedeptin as a potential solution by remodeling the tumor microenvironment, promoting immune activation, and enhancing responsiveness to checkpoint inhibitors. 'Gedeptin is not necessarily intended to directly compete with checkpoint inhibitors, but rather to complement them,' Dodd added.

GeoVax's lead development focus for Gedeptin is a planned neoadjuvant study in recurrent head and neck squamous cell carcinoma (HNSCC), evaluating intratumoral Gedeptin in combination with PD-1-based immunotherapy. The company considers recurrent head and neck cancer an attractive initial setting due to accessible tumors and established checkpoint inhibitor use. 'As checkpoint inhibitors continue moving earlier in the treatment paradigm, opportunities are emerging for therapies designed to improve immune responsiveness before surgery,' Dodd said.

Beyond head and neck cancer, GeoVax sees potential for Gedeptin across multiple solid tumors where checkpoint inhibitors are standard but response rates are suboptimal. The company believes its platform could expand the impact of checkpoint blockade. For more information, visit www.geovax.com.